Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer
Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: Karger
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: Karger
Subjects
More information
Scope and Contents
Contents
24 patients were enrolled into a phase I–II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential combination and the response rate in platinum/paclitaxel resistant ovarian cancer patients. A total of 83 courses are evaluable, with a median number of three cycles administered per patients (range 2–7). Topot...
Alternative Titles
Full title
Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_220884063
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_220884063
Other Identifiers
ISSN
0030-2414
E-ISSN
1423-0232
DOI
10.1159/000055291
